drugset

drugset / Trial / NCT06603246

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT06603246 ↗

Phase 1 Recruiting 128 enrolled Genentech, Inc.

NaSequentialOpen-labelTreatment

Summary

This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.

Timeline

Start: 2024-11-18
Primary completion: 2027-11-15
Completion: 2027-11-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GDC-6988	Unknown	—	Inhaled

Indications